171 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
PF Pinnacle Foods, Inc. $67.54 $8.05B N/A
Article Searches
Merck's Keytruda Meets PFS Endpoint in Breast Cancer Study http://www.zacks.com/stock/news/763946/mercks-keytruda-meets-pfs-endpoint-in-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-763946 Feb 13, 2020 - Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.
Merck's Keytruda meets PFS endpoint in TNBC study https://seekingalpha.com/news/3540935-mercks-keytruda-meets-pfs-endpoint-in-tnbc-study?utm_source=feed_news_all&utm_medium=referral Feb 12, 2020 - Merck (NYSE:MRK) announces that a Phase 3 clinical trial, KEYNOTE-355, evaluating the combination of Keytruda (pembrolizumab) and chemo in patients with metastatic triple-negative breast cancer (T
Provident Financial Services, Inc.'s (PFS) CEO Chris Martin on Q4 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4320684-provident-financial-services-inc-s-pfs-ceo-chris-martin-on-q4-2019-results-earnings-call?source=feed_sector_financial Jan 31, 2020 - Provident Financial Services, Inc. (NYSE:PFS) Q4 2019 Results Earnings Conference Call January 31, 2020, 10:00 AM ET Company Participants Len Gleason - Investor Relations Officer Chris Martin - Chairm
Provident Financial Services, Inc (PFS) Q4 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/01/31/provident-financial-services-inc-pfs-q4-2019-earni.aspx?source=iedfolrf0000001 Jan 31, 2020 - PFS earnings call for the period ending January 31, 2020.
Provident Financial Services Inc (PFS) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/10/25/provident-financial-services-inc-pfs-q3-2019-earni.aspx?source=iedfolrf0000001 Oct 25, 2019 - PFS earnings call for the period ending September 30, 2019.
Provident Financial Services, Inc. (PFS) CEO Chris Martin on Q2 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4299274-provident-financial-services-inc-pfs-ceo-chris-martin-q2-2019-results-earnings-call?source=feed_sector_financial Oct 25, 2019 - Provident Financial Services, Inc. (NYSE:PFS) Q2 2019 Earnings Conference Call October 25, 2019 10:00 AM ET Company Participants Len Gleeson - Investor Relations John Kuntz - Corporate Secretary Chris
Provident Financial (PFS) Q3 Earnings and Revenues Beat Estimates http://www.zacks.com/stock/news/583910/provident-financial-pfs-q3-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-583910 Oct 25, 2019 - Provident Financial (PFS) delivered earnings and revenue surprises of 8.89% and 1.30%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Glaxo's Zejula Betters PFS in First-Line Ovarian Cancer Study http://www.zacks.com/stock/news/542861/glaxos-zejula-betters-pfs-in-first-line-ovarian-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-542861 Sep 30, 2019 - Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer significantly reduces risk of disease progression or death by 38%.
AstraZeneca/Merck's Lynparza Improves PFS in Frontline Study http://www.zacks.com/stock/news/542841/astrazeneca-mercks-lynparza-improves-pfs-in-frontline-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-542841 Sep 30, 2019 - AstraZeneca's (AZN) Lynparza reduces the risk of disease progression by 41% in a study, evaluating the PARP inhibitor as a first-line maintenance treatment in women with advanced ovarian cancer.
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study http://www.zacks.com/stock/news/520871/amgens-kyprolis-combo-improves-pfs-in-multiple-myeloma-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-520871 Sep 16, 2019 - Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.

Pages: 123456...18

Page 1>